viewConatus Pharmaceuticals Inc

Conatus Pharmaceuticals shares tank after missing primary endpoint in clinical trial of its liver disease drug

Results from the Phase 2b clinical trial of liver disease drug Emriscan failed to show a meaningful difference when compared with the placebo

Scientist sitting in a lab and looking into a microscope
Conatus focuses on the development of therapies to treat liver disease

Conatus Pharmaceuticals Inc (NASDAQ:CNAT) shares lost about half their value in Thursday pre-market trading following disappointing results from its Phase 2b clinical trial of its liver disease drug Emriscan.

The biotech’s ENCORE-PH clinical trial found that Emriscan failed to meet the primary endpoint of the study after being unable to show a meaningful difference when compared with the placebo.

READ: BioTime shares pop following positive preclinical results from its HyStem drug delivery platform

Shares fell 51% to $2.20 in Thursday pre-market trading.

Emriscan is an oral drug designed to reduce the activity of enzymes that cause inflammation and cell death, which may be able to affect the progression of liver disease.

“We believe data from the ENCORE-PH clinical trial as well as data from our two ongoing ENCORE trials that will be available in 2019 will warrant future discussions with regulatory authorities regarding potential pivotal trials in patients with NASH and advanced liver disease,” said Executive Vice President of Clinical Development David T. Hagerty in the company’s press release.

The double-blind, placebo-controlled study, conducted alongside drug manufacturing giant Novartis AG (NYSE:NVS), enrolled 263 patients with nonalcoholic steatohepatitis, a condition caused by a buildup of fat in the liver resulting in inflammation and damage to the organ.

Conatus is a San Diego-based biotech focused on the development of therapies to treat liver disease.


Contact Lenore Fedow at [email protected]

Follow her on Twitter@LenoreMariee

Quick facts: Conatus Pharmaceuticals Inc

Price: 0.465 USD

Market: NASDAQ
Market Cap: $15.42 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Full interview: Polarean Imaging achieves positive phase III results in two...

Polarean Imaging PLC (LON:POLX) CEO Richard Hullihen tells Proactive its two phase III clinical trials have 'demonstrated handily' that its technology allows doctors and surgeons to visualize aspects of lung function that have gone undetected using traditional magnetic resonances imaging (MRI)...

2 hours, 14 minutes ago

2 min read